Ger Brophy leads the Cell Therapy business in GE Healthcare Life Sciences. Life Sciences in GE is a $4.5 billion + molecular medicine business that provides industry-leading technologies and services for drug discovery, clinical development and biopharmaceutical manufacturing, as well as molecular tools for therapy selection and treatment monitoring in patient care.
Previously Ger was Chief Technology Officer of GE Healthcare Life Sciences. In this role, he is responsible for the technology and R&D strategy of the business; including developing process for driving innovation in such a large company. Sitting on the GE Healthcare Strategy council, he also has oversight of integrated initiatives across all aspects of Healthcare Diagnostics
Ger has over twenty years’ experience in the global life sciences and biotechnology industry. Previously he was Head of New Product Development at GE Healthcare Medical Diagnostics; encompassing the development of in vivo and in vitro diagnostic technologies, with oversight of discovery (research) and clinical development; regulatory and medical affairs; project and portfolio management; product acquisition and licensing; R&D efficiency projects and collaborations across GE.
He has also led Strategic Planning & Licensing within the Medical Diagnostics business and was centrally involved in the expansion of the business into the Personalized Medicine space.
He has held international assignments in the UK, Sweden and in Chicago & New Jersey.
Ger holds a Ph.D. in Molecular Biology from Dublin City University, Ireland. He is a Fellow of the Royal Society of Chemistry and holds directorship positions in Biosafe, Asymptote, Medi-Physics & Drawbridge. In the UK, he is a member of the National Advanced Therapy Manufacturing Taskforce and is a member of the Catapult Scientific Advisory Committee for Cell Therapy.
10:30 AM–11:45 AM Jun 7, 2018 (US - Eastern)